Advice for patients following availability of new weight-loss treatment

Since Monday 23 June, a new weight loss drug called tirzepatide, sometimes referred to as Mounjaro®, has been made available for use in primary care settings.

In line with NHS England guidance, this treatment will only be available for patients whose body mass index is above 40 and have been diagnosed with four or more obesity-related health conditions.

These conditions include:

• Type 2 diabetes
• Hypertension
• Cardiovascular disease
• Obstructive sleep apnoea
• Dyslipidaemia

Access will be prioritised for those with the greatest clinical need, as the treatment is only intended to support people living with health conditions caused or made worse by obesity.

The ICB is currently working with colleagues in primary care to ensure this new treatment is offered to those patients who fulfil this criteria.

All patients, including those who may be eligible for the new drug, are continued to be encouraged to access NHS-supported healthy living initiatives, such as diet support and activity groups, as part of their overall weight loss journey.